Standard Biotools (LAB) Net Cash Flow (2010 - 2026)

Standard Biotools (LAB) has 17 years of Net Cash Flow data on file, last reported at $144.5 million in Q1 2026.

• On a quarterly basis, Net Cash Flow rose 1019.85% year-over-year to $144.5 million in Q1 2026; TTM through Mar 2026 was $113.8 million, a 184.63% increase from a year earlier, with the FY2025 full-year figure at -$46.4 million, down 139.59% from the prior year.
• Net Cash Flow for Q1 2026 stood at $144.5 million, up from -$8.6 million in the prior quarter.
• Over the last five years, Net Cash Flow for LAB reached as high as $235.9 million in Q1 2024 and fell as low as -$62.5 million in Q3 2023.
• Historically, Net Cash Flow has averaged $14.0 million across 5 years, with a median of -$8.6 million in 2025.
• On a YoY basis, Net Cash Flow climbed as much as 1885.84% in 2023 and fell as far as 350.3% in 2023.
• Year by year, Net Cash Flow stood at $20.8 million in 2022, then plunged by 235.52% to -$28.2 million in 2023, then tumbled by 52.06% to -$42.9 million in 2024, then jumped by 79.91% to -$8.6 million in 2025, then surged by 1777.74% to $144.5 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $144.5 million in Q1 2026, -$8.6 million in Q4 2025, and -$29.0 million in Q3 2025.